Truist Securities Maintains Buy on Alnylam Pharmaceuticals, Lowers Price Target to $315

Benzinga Newsdesk www.benzinga.com Negative 68.2%

Neg 68.2% Neu 0% Pos 0%

Truist Securities analyst Danielle Brill maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and lowers the price target from $410 to $315.